Micron Technology, Inc. (NASDAQ:MU) shares moved up 0.28% in last trading session and ended the day at $10.75. MU Gross Margin is 26.20% and its has a return on assets of 4.30%. Micron Technology, Inc. (NASDAQ:MU) quarterly performance is 6.97%.
On 15 April, Micron Technology, Inc. (NASDAQ:MU) announced the pricing of an offering of $1.25 billion aggregate principal amount of its 7.500% senior secured notes due 2023 (the “Notes”). The size of the offering was increased from the previously announced $1.0 billion in aggregate principal amount.
Medivation, Inc. (NASDAQ:MDVN) ended the last trading day at $51.38. Company weekly volatility is calculated as 5.08%. Medivation, Inc. (NASDAQ:MDVN) showed a weekly performance of 4.07%.
On 18 April, Medivation, Inc. (NASDAQ:MDVN) reported successful early-stage cancer data as buyout rumors continued to circle the company.
On 20 April, CBIZ, Inc. (NYSE:CBZ) shares decreased -0.68% and was closed at $10.18. CBZ EPS growth in last 5 year was 6.50%. CBIZ, Inc. (NYSE:CBZ) year to date (YTD) performance is 3.25%.
CBIZ, Inc. (NYSE:CBZ) said it has acquired The Savitz Organization, a Philadelphia-based employee retirement and health and welfare benefits firm.
Grupo Financiero Galicia S.A. (NASDAQ:GGAL) shares decreased -1.54% in last trading session and ended the day at $30.62. GGAL has a return on assets of 5.00%. Grupo Financiero Galicia S.A. (NASDAQ:GGAL) quarterly performance is 27.90%.
Investment analysts at Credit Suisse began coverage on shares of Grupo Financiero Galicia S.A. (NASDAQ:GGAL) in a research report issued to clients and investors on Tuesday, The Fly reports. The brokerage set a “neutral” rating and a $31.00 price target on the stock. Credit Suisse’s target price would suggest a potential upside of 9.46% from the company’s previous close.
OncoSec Medical Incorporated (NASDAQ:ONCS) caters to the Healthcare space. Its weekly performance is -4.32%. On the last day of trading company shares ended up at $2.66. OncoSec Medical Incorporated (NASDAQ:ONCS) distance from 50-day simple moving average (SMA50) is 5.54%.
OncoSec Medical Incorporated (NASDAQ:ONCS) presented long-term, follow-up data of patients who were treated with its investigational therapy ImmunoPulse IL-12 and later went on to receive an anti-PD-1/PD-L1 therapy. These data suggest that ImmunoPulse™ IL-12 may prime and enhance response rates to PD-1/PD-L1 blockade. Alain Algazi, MD, skin cancer specialist in the Melanoma Center at the UCSF Helen Diller Family Comprehensive Cancer Center, presented the findings in an oral presentation entitled “Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma” (Abstract #CT134) at the American Association of Cancer Research (AACR) Annual Meeting in New Orleans, LA.
Leave a Reply